Individual symptoms of CNS stimulation have been noted in trials for extended-release formulations of tramadol, including nervousness (less than 5%), anxiety (1% to less than 5%), agitation (less than 5%), depression (less than 5%), tremor (1% to less than 5%), euphoria (less than 5%), emotional disturbance (less than 1%), paresthesias (less than 5%), and hypertonia (less than 5%)
These consequences may, in turn, increase healthcare utilization and associated costs through additional diagnostic testing, clinic visits, or hospitalizations
This rare genetic condition increases cancer risk, and these medications may add to that concern
The outcome of this lawsuit will not only affect the availability of tirzepatide but could also reshape the relationship between the FDA, drug manufacturers, and compounders in the future